We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+16.43%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.68B
AUM Growth
+$199M
Cap. Flow
-$1.42B
Cap. Flow %
-30.22%
Top 10 Hldgs %
50.13%
Holding
119
New
17
Increased
19
Reduced
10
Closed
18

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$29M
2
RVNC
Revance Therapeutics, Inc.
RVNC
+$27.1M
3
APLS
Apellis Pharmaceuticals
APLS
+$27M
4
AMED
Amedisys
AMED
+$25.5M
5
RVMD icon
Revolution Medicines
RVMD
+$22.6M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$52.3M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$48.8M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$39.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$36.6M
5
CPRX
Catalyst Pharmaceutical
CPRX
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 68.03%
2 Financials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FDMT icon
51
4D Molecular Therapeutics
FDMT
$588M
$11.7M 0.25%
+650,000
New +$12M
VSTM icon
52
Verastem
VSTM
$510M
$11.4M 0.24%
+1,538,461
New +$10.7M
AXNX
53
DELISTED
Axonics, Inc. Common Stock
AXNX
$11.4M 0.24%
+225,000
New +$12M
ALHC icon
54
Alignment Healthcare
ALHC
$4.4B
$10.6M 0.23%
+1,842,000
New +$11.9M
NUVB icon
55
Nuvation Bio
NUVB
$2.2B
$10.5M 0.23%
5,854,860
– –
MRSN
56
DELISTED
Mersana Therapeutics
MRSN
$9.49M 0.2%
+115,416
New +$16.9M
PHAT icon
57
Phathom Pharmaceuticals
PHAT
$855M
$9.39M 0.2%
+656,000
New +$7.56M
BCRX icon
58
BioCryst Pharmaceuticals
BCRX
$2.35B
$9.31M 0.2%
1,322,000
-1,443,000
-52% -$11.6M
BDTX icon
59
Black Diamond Therapeutics
BDTX
$102M
$9.09M 0.19%
+1,800,000
New +$3.68M
WGS icon
60
GeneDx Holdings
WGS
$1.83B
$7.47M 0.16%
1,253,895
-479,199
-28% -$3.79M
ALEC icon
61
Alector
ALEC
$160M
$6.34M 0.14%
1,055,192
– –
FHTX icon
62
Foghorn Therapeutics
FHTX
$308M
$5.47M 0.12%
777,525
– –
OMIC
63
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$5.35M 0.11%
215,029
– –
NYXH
64
Nyxoah
NYXH
$156M
$3.65M 0.08%
455,262
– –
ABEO icon
65
Abeona Therapeutics
ABEO
$371M
$3.5M 0.07%
869,565
– –
ROIVW
66
DELISTED
Roivant Sciences Ltd. Warrant
ROIVW
$2.48M 0.05%
1,000,000
– –
AFIB
67
DELISTED
Acutus Medical Inc
AFIB
$2.36M 0.05%
2,660,808
+9,141
+0.3% +$7.75K
ELEV
68
DELISTED
Elevation Oncology
ELEV
$2.1M 0.04%
+1,381,416
New +$3.64M
ANNX icon
69
Annexon
ANNX
$926M
$2.06M 0.04%
583,913
– –
TOI icon
70
The Oncology Institute
TOI
$545M
$1.85M 0.04%
3,360,052
– –
ORTX
71
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.65M 0.04%
316,169
– –
QSI icon
72
Quantum-Si Incorporated
QSI
$180M
$1.43M 0.03%
+797,500
New +$1.25M
CALC icon
73
CalciMedica
CALC
$11.2M
$1.07M 0.02%
+265,657
New +$1.16M
CMAXW
74
DELISTED
CareMax, Inc. Warrant
CMAXW
$259K 0.01%
672,000
– –
MDVL
75
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$205K ﹤0.01%
16,733
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2023 Portfolio in Review

As of Q2 2023, Deerfield Management held 119 positions worth $4.68B, up 4.4% from $4.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Deerfield Management withdrew a net $1.42B in Q2 2023, closing 18 positions and reducing 10 holdings. Its most notable exit was Mirum Pharmaceuticals, an estimated $48.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 63% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Intercept Pharmaceuticals, Inc. worth $23M.

  • Deerfield Management's largest Q2 2023 buy was Intercept Pharmaceuticals, Inc.: 2,077,893 shares worth $23M.
  • Deerfield Management added most to Amedisys in Q2 2023, an estimated $25.5M increase.
  • Deerfield Management's biggest Q2 2023 reduction was Neurocrine Biosciences, cutting an estimated $52.3M.
  • Deerfield Management fully exited Mirum Pharmaceuticals in Q2 2023, selling an estimated $48.8M.
  • Deerfield Management's ten largest holdings make up 50% of its $4.68B portfolio in Q2 2023.
  • Deerfield Management opened 17 new positions and closed 18 in Q2 2023.
  • Deerfield Management's portfolio value rose 4.4% quarter-over-quarter to $4.68B.

Based on Deerfield Management's 13F filing for Q2 2023, filed 14 Aug 2023.